Zollinger-Ellison Syndrome: The Esophageal Stricture as a Rare and Severe Complication Abstract #848

Introduction: Zollinger-Ellison Syndrome (ZES) is caused by tumoral hypersecretion of gastrin, inducing gastric hyperchlorhydria and complicated peptic ulcer disease. Esophageal strictures are rare in ZES, due to early PPI treatment.
Aim(s): To evaluate clinical presentation, treatment, histology and prognosis.
Materials and methods: From 2004 to 2013, we observed three patients with ZES with severe esophageal strictures (out of 20 observed). Endoscopy and barium esophagram performed to detect the esophageal strictures and establish their severity and extension. ZES established by fasting serum gastrin or secretin provocative test, and gastric acid studies. Octreoscan scintigraphy performed for detecting tumor localization.
Conference: 11th Annual ENETS Conference (2014)
Category: Surgical treatment
Presenting Author: Claudio Pasquali

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1069 Gastric Neuroendocrine Neoplasms and Long-Term Proton Pump Inhibitors: Need for a Revision of Classifications?
Introduction: Gastric neuroendocrine neoplasm (gNENs) include three types: type 1 and 2 related to hypergastrinemia due to chronic atrophic gastritis(CAG) or Zollinger-Ellison syndrome (ZES) respectively, and type 3 normogastrinemic and more aggressive. Few cases of gNENs in patients taking proton pump inhibitors (PPI) have been reported
Conference: 12th Annual ENETS Conference (2015)
Category: Clinical cases/reports
Presenting Author: MD Federica Cavalcoli
Keywords: PPI, gNEN, classification, CAG
#1756 Somatostatin Analogs in Patients with Multiple Endocrine Neoplasia Type 1 and Zollinger-Ellison Syndrome: Efficacy and Safety
Introduction: Zollinger-Ellison syndrome (ZES) can cause severe complications. In multiple endocrine neoplasia type 1 (MEN1) related ZES, surgery has a controversial role and proton pump inhibitors (PPI) are usually first-line therapy, although some concerns regarding long-term use. Somatostatin analogs (SSA) both reduce hypergastrinemia and have an antiproliferative role.
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: MD Roberta Modica
#520 Left Pancreatectomy for Neuroendocrine Pancreatic Tumors
Introduction: Distal pancreatectomy for neuroendocrine tumors localized in the body-tail of the pancreas (NTP) can be performed either with splenectomy (DP) or with a spleen-preserving procedure (SPLP).
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Prof. Claudio Pasquali
#523 Metastatic Midgut Carcinoid Tumors: 20-years Experience in a Single Center
Introduction: The prognosis of metastatic midgut carcinoids has improved during the last decade, due to the increasing number of therapeutic options.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Prof. Claudio Pasquali
#525 Pancreatic Neuroendocrine Tumors Associated with Mesenchimal Neoplasms of the GI Tract
Introduction: Neuroendocrine pancreatic tumors (NPT) are occasionally associated with mesenchimal tumors in neurofibromatosis type 1 but rarely in sporadic cases. We report five cases of NPT associated with other rare mesenchimal neoplasms of the GI tract, observed in our Department from 2003 to 2011.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Prof. Claudio Pasquali